Heron Therapeutics: Corporate Presentation (Heron Therapeutics) - Jan 17, 2016 - "HTX-019 was clearly better tolerated than EMEND IV, with 62% fewer AEs at least possibly related to treatment, no AEs of greater than mild severity, no premature discontinuation and no hypersensitivity reaction"
Clinical data • Oncology
|